BEIJING: A cluster of high-end medical device manufacturers is taking shape in Beijing’s Changping district, as the capital steps up efforts to strengthen domestic innovation and reduce reliance on imported technologies.
The Champion Bio has rapidly evolved into a key hub for high-end medical devices, precision medicine, new drug development and biotechnology, with a focus on three core segments — advanced equipment, high-value medical consumables and efficient diagnostics.
Aligned with trends including digitalisation, intelligent technologies and personalised healthcare, the park is building an industrial framework covering emerging fields such as brain-inspired intelligence, implantable devices and medical aesthetics equipment, while strengthening clinical application as a key driver of innovation.
Inside the park, research centres and production facilities house a growing number of technology-driven companies.
Among them is TowardPi Medical, whose core technologies originated from Tsinghua University and were incubated through its research institutes.
The company has developed a full range of high-end ophthalmic equipment, including optical coherence tomography (OCT) systems and surgical microscopes.
Its OCT products have been installed in more than 1,000 units domestically over four years, with market share ranking among the top in China.
The products have also been exported to over 50 countries and regions, gaining traction in markets such as Germany, Italy, France and Singapore.
Wang Yingqi, co-founder and general manager of TowardPi Medical, said the company began overseas sales in 2024 and recorded more than US$10mil in international revenue in 2025, with about 70% coming from European markets.
“Our growth is driven by technological innovation rather than low-price competition,” Wang said.
“In key performance indicators such as scanning speed, imaging depth and coverage, our products have reached leading levels globally.”
Nearby, New Cloud Medical is focusing on innovative devices targeting chronic pain and neurostimulation.
The company has built an integrated research model combining clinical expertise, materials science and algorithm development, with products covering minimally invasive procedures and implantable stimulation systems.
Some of its core products, including an artificial intelligence-powered closed-loop spinal cord stimulation system, aim to break foreign technological monopolies and offer more precise and effective treatment options for patients.
In addition to the two companies, more than 40 enterprises have already settled in the park, covering multiple segments of the medical device industry and forming an initial industrial cluster. — China Daily/ANN
